OCUMENSION-B (01477) has announced the completion of patient enrollment for its Phase III clinical trial of OT-211 (TRYPTYR® acotiamide eye drops) in the People's Republic of China, with a total of 398 patients recruited. OT-211 is a 0.003% concentration eye drop formulation and is the first TRPM8 agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of dry eye disease (DED).

In March 2026, the first patient was dosed in the Phase III trial in China, marking a significant milestone in the clinical development of OT-211 in the region and underscoring the group's commitment to advancing innovative therapies for DED patients. Alcon Inc. (together with its affiliates, the "Alcon Group"), a global leader in eye care with operations spanning two complementary segments—surgical and vision care—developed the 0.003% formulation of AR-15512 and completed one Phase IIb and three Phase III trials. OT-211 received FDA approval on May 28, 2025, for treating both signs and symptoms of DED. Following the strategic collaboration with the Alcon Group in October 2024, the company has secured an exclusive license from Alcon to develop, manufacture, contract manufacture, import, export, and sell OT-211 in mainland China. The successful enrollment for OT-211 not only marks a strong partnership and close collaboration with the Alcon Group in new drug development, but also lays the groundwork for future joint exploration and advancement of novel therapies.